{"related:zz01jANhUvgJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5":[{"title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","url":"http://pfizerpro.com.s3.amazonaws.com/fixtures/oncology/docs/interferon.pdf","authors":["RJ Motzer","RJ Motzer J Bacik","RJ Motzer J Bacik BA Murphy…"],"year":2002,"numCitations":1668,"pdf":"http://pfizerpro.com.s3.amazonaws.com/fixtures/oncology/docs/interferon.pdf","citationUrl":"http://scholar.google.com/scholar?cites=17893470937361497551&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:zz01jANhUvgJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=17893470937361497551&hl=en&as_sdt=0,5","publication":"pfizerpro.com.s3.amazonaws.com","p":1,"exp":1596898399269},{"title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results …","url":"https://confkhalifa.com/trainingkhalifa/wp-content/uploads/2017/05/DP-2-LCA-ARTICLE-The%CC%81o-PEZEL-CB-avril-2017-anglais.pdf","authors":["DYC Heng","DYC Heng W Xie","DYC Heng W Xie MM Regan","DYC Heng W Xie MM Regan MA Warren…"],"year":2009,"numCitations":1433,"pdf":"https://confkhalifa.com/trainingkhalifa/wp-content/uploads/2017/05/DP-2-LCA-ARTICLE-The%CC%81o-PEZEL-CB-avril-2017-anglais.pdf","citationUrl":"http://scholar.google.com/scholar?cites=4181130477325190870&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:1gaHPARcBjoJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4181130477325190870&hl=en&as_sdt=0,5","publication":"confkhalifa.com"},{"title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/nejmoa065044","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson P Tomczak…"],"year":2007,"numCitations":6133,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa065044","citationUrl":"http://scholar.google.com/scholar?cites=12674526305022444340&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:NAM1m4X25K8J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=12674526305022444340&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell …","url":"https://pdfs.semanticscholar.org/ee55/13caa9147d9690ae6c0e1df1560526cb55d8.pdf","authors":["TM Mekhail","TM Mekhail RM Abou"],"year":2005,"numCitations":581,"pdf":"https://pdfs.semanticscholar.org/ee55/13caa9147d9690ae6c0e1df1560526cb55d8.pdf","citationUrl":"http://scholar.google.com/scholar?cites=16029174362600267529&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:CV-WFSgRc94J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16029174362600267529&hl=en&as_sdt=0,5","publication":"pdfs.semanticscholar.org"},{"title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa066838","authors":["G Hudes","G Hudes M Carducci","G Hudes M Carducci P Tomczak…"],"year":2007,"numCitations":4021,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa066838","citationUrl":"http://scholar.google.com/scholar?cites=11854457709475007825&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:UQ0mqnp-g6QJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11854457709475007825&hl=en&as_sdt=0,5","publication":"Mass Medical Soc"},{"title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","url":"http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.965.6583&rep=rep1&type=pdf","authors":["RJ Motzer","RJ Motzer M Mazumdar","RJ Motzer M Mazumdar J Bacik","RJ Motzer M Mazumdar J Bacik W Berg…"],"year":1999,"numCitations":1851,"pdf":"http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.965.6583&rep=rep1&type=pdf","citationUrl":"http://scholar.google.com/scholar?cites=16620025474542165120&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:gFwHyBwxpuYJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16620025474542165120&hl=en&as_sdt=0,5","publication":"Citeseer"},{"title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","url":"https://www.sciencedirect.com/science/article/pii/S0140673607619047","authors":["B Escudier","B Escudier A Pluzanska","B Escudier A Pluzanska P Koralewski","B Escudier A Pluzanska P Koralewski A Ravaud…"],"year":2007,"numCitations":2570,"pdf":"https://journals.viamedica.pl/nowotwory_journal_of_oncology/article/download/52342/39075","citationUrl":"http://scholar.google.com/scholar?cites=5427817888518646484&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:1Cqqnpx7U0sJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=5427817888518646484&hl=en&as_sdt=0,5","publication":"Elsevier"},{"title":"Immunotherapy for advanced renal cell cancer","url":"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001425.pub2/abstract","authors":["C Coppin","C Coppin F Porzsolt","C Coppin F Porzsolt M Autenrieth…"],"year":2004,"numCitations":890,"citationUrl":"http://scholar.google.com/scholar?cites=16037437521858945892&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ZGPsxXRskN4J:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16037437521858945892&hl=en&as_sdt=0,5","publication":"cochranelibrary.com"},{"title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3646307/","authors":["RJ Motzer","RJ Motzer TE Hutson","RJ Motzer TE Hutson P Tomczak…"],"year":2009,"numCitations":2287,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3646307/","citationUrl":"http://scholar.google.com/scholar?cites=9930987091739607833&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:GQMhsCT00YkJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=9930987091739607833&hl=en&as_sdt=0,5","publication":"ncbi.nlm.nih.gov"},{"title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","url":"http://s-space.snu.ac.kr/handle/10371/77398","authors":["CN Sternberg","CN Sternberg ID Davis","CN Sternberg ID Davis J Mardiak…"],"year":2010,"numCitations":2448,"pdf":"http://s-space.snu.ac.kr/bitstream/10371/77398/1/Sternberg-2010-Pazopanib%20in%20Locally.pdf","citationUrl":"http://scholar.google.com/scholar?cites=17868513553253356300&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:DFPrvWe2-fcJ:scholar.google.com/&scioq=&hl=en&as_sdt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=17868513553253356300&hl=en&as_sdt=0,5","publication":"s-space.snu.ac.kr"}]}